CTLA4 and neoplasm: Oral and systemic administration of inosine can improve the efficacy of ICIs that target the immune checkpoint cytotoxic T lymphocyte-associated protein 4 (CTLA-4), thus reducing tumor weights and enhancing antitumor immunity.